Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms
Clémence Marcault, Lin‐Pierre Zhao, Nabih Maslah, Emmanuelle Verger, Rafael Daltro De Oliveira, Juliette Soret‐Dulphy, Marine Cazaux, Nicolas Gauthier, Blandine Roux, Emmanuelle Clappier, Nathalie Parquet, Christine Dosquet, Delphine Réa, Jean‐Marc Zini, William Vainchenker, Emmanuel Raffoux, Stéphane Giraudier, Jean‐Jacques Kiladjian, Bruno Cassinat, Lina Benajiba
Abstract
Marcault et al report the impact of NFE2 mutations on the prognosis of patients with myeloproliferative neoplasms (MPNs) in a study of over 700 patients for whom sequential next-generation sequencing was available. NFE2 mutations were reported in 9.1% of patients and predicted for increased transformation and decreased survival. Since histone deacetylase (HDAC) inhibitors decrease NFE2 levels, patients with NFE2 mutations may benefit from HDAC inhibitors.